RNA and cancer;ARN et cancer

Bulletin du Cancer

Volumn 95, Issue 1, 2008, Pages 33-41

  Jeanteur, Philippe ^a  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

Alternative splicing; Gene expression; MicroRNAs; Oncogenes; Tumor suppressor genes

Indexed keywords

MICRORNA; RNA;

ALTERNATIVE RNA SPLICING; CANCER INHIBITION; CHROMOSOME ABERRATION; DIAGNOSTIC PROCEDURE; EXON; GENE EXPRESSION; GENE LOCUS; GENETIC VARIABILITY; HUMAN; METAZOON; NEOPLASM; NUCLEOTIDE SEQUENCE; ONCOGENE; POINT MUTATION; PROGNOSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; GENE EXPRESSION REGULATION; GENETICS; INTRON; MUTATION; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTRONS; MICRORNAS; MUTATION; NEOPLASMS; RNA, NEOPLASM;

EID: 39149137282     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0554     Document Type: Review

References (36)

1. Dani C, et al. Extreme unstability of myc mRNA in normal and transformed human cells. Proc Natl Acad Sci USA 1984 ; 81 : 7046-50.
2. Scholzova E, Malik R, Sevcik J, Kleibel Z. RNA regulation and cancer development. Cancer Lett 2007 ; 246 : 12-23.
3. Leff SE, Evans RM, Rosenfeld MG. Splice commitment dictates neuron-specific alternative RNA processing in calcitonin/CGRP gene expression. Cell 1987 ; 48 : 517-24.
4. Schmucker D, et al. Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell 2000 ; 101 : 671-84.
5. Johnson JM, et al. Genome-wide survey of human alternative splicing with exon-junction microarrays. Science 2003 ; 302 : 2141-4.
6. Modrek B, Resch A, Grasso C, Lee C. Genome-wide analysis of alternative splicing using human expressed sequence data. Nucleic Acids Res 2001 ; 29 : 2850-9.
7. Stickeler E, Kittrell F, Medina D, Berget S. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999 ; 18 : 3574-82.
8. Fischer DC, et al. Expression of splicing factors in human ovarian cancer. Oncol Rep 2004 ; 11 : 1085-90.
9. Kirschbaum-Slager N, Lopes GMP, Galante PAF, Riggins GJ, de Souza SJ. Splicing factors are differentially expressed in tumors. Gen Mol Res 2004 ; 3 : 512-20.
10. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer A. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007 ; 14 : 185-93.
11. Rossi F, et al. Mammalian DNA topoisomerase I specifically posphorylates SR protein splicing factors. Nature 1996 ; 381 : 80-2.
12. Jeanteur P. L'ADN topoisomérase I : une cible double pour les drogues anti-cancéreuses. Bull Cancer 1997 ; 84 : 190.
13. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004 ; 64 : 7647-54.
14. Brinkman BMN. Splice variants as cancer modulators. Clin Biochem 2004 ; 37 : 584-94.
15. Pajares MJ, Ezponda T, Catena R, Calvo A, Pia R, Montuenga LM. Alternative splicing : an emerging topic in molecular and clinical oncology. Lancet Oncol 2007 ; 8 : 349-57.
16. Skotheim RI, Nees M. Alternative splicing and cancer : noise, functional or systematic? Int J Biochem Cell Biol 2007 ; 30 : 1432-49.
17. Boise LH, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993 ; 74 : 597-608.
18. Douc-Rasy S, Bénard J. p53, p63, p73 : un véritable air de famille, enfin ! Bull Cancer 2005 ; 92 : 933-4.
19. Bourdon JC, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005 ; 19 : 2122-37.
20. Murray-Zmijewsky F, Lane D, Bourdon JC. p53/p63/p73 isoforms : an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006 ; 13 : 962-72.
21. Ghigna C, et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005 ; 20 : 881-90.
22. Soret J, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc Natl Acad Sci USA 2005 ; 102 : 8764-9.
23. Tazi J, Durand S, Jeanteur P. The spliceosome : a novel multi-faceted target for therapy. Trends Biochem Sci 2005 ; 30 : 469-78.
24. Jeanteur P. L'épissage alternatif : une nouvelle cible pharmacologique pour des petites molécules chimiques. Bull Cancer 2005 ; 92 : 632.
25. Esquela-Kerscher A, Slack FJ. Oncomirs : microRNAs with a role in cancer. Nat Rev Cancer 2006 ; 6 : 259-69.
26. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006 ; 6 : 857-66.
27. Bénard J, Douc-Rasy S. Micro-ARN et oncogenèse. Bull Cancer 2005 ; 92 : 757-62.
28. Calin GA, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004 ; 101 : 2999-3004.
29. Calin GA, et al. Frequent deletions and down-regulation of micro-RNA genes miR 15 and miR 16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002 ; 99 : 15524-9.
30. Cimmino A, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005 ; 102 : 13944-9.
31. Johnson SM, et al. RAS is regulated by the let-7 MicroRNA family. Cell 2005 ; 120 : 635-47.
32. Costinean S, et al. Pre-B cell proliferation and lymphoblastic leukemia/high grade lymphoma in E (mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006 ; 103 : 7024-9.
33. Volinia S, et al. A microRNA expression signature of human solid tumors define cancer gene targets. Proc Natl Acad Sci USA 2006 ; 103 : 2257-61.
34. Yanaihara N, et al. microRNA signature in lung cancer diagnosis and prognosis. Cancer Cell 2006 ; 9 : 189-98.
35. Liu CG, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004 ; 101 : 9740-4.
36. Lu J, et al. MicroRNA expression profile classify human cancers. Nature 2005 ; 435 : 834-8.